Blog

Nov 15, 2024, 16:14

Epco in first line older Diffuse large B-cell lymphoma

Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared on X:

“Epco in 1L older DLBCL:

– 45 patients, med age 81, 58% IPI 3+

– ORR 74%, CR 64%, 6-mo OS 76%

– 16% d/c’d d/t TEAEs, 4 G5 events!

– low rates G3 CRS/ICANS

Still early f/u (50% still on tx) but promising time-limited approach for multimorbid/frail. ”

Paper: Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older, Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Authors: Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier Lopez Jimenez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, and Sherida Woei-A-Jin

Epco in first line older Diffuse large B-cell lymphoma

Ajay Major and Sherida Woei-A-Jin cancer Caressa Meert Catherine Thieblemont Daniela Hoehn David Belada Evelyn Guo Javier López-Jiménez Johannes Duell Mina Khoshdeli OncoDaily Oncology ranck Morschhauser Sergio Ortegon Alcaide Tae Min Kim Takahiro Kumode Wojciech Jurczak Won Seog Kim Yajian Jiang Yanli Wang

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology